methyl (E)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hept-6-enoate | 884864-20-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: methyl (E)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hept-6-enoate
• CAS: 884864-20-4
• 化学式: C₁₄H₂₅BO₄
• 分子量: 268.161
• InChiKey: SQIZTFVAYSBHAT-PKNBQFBNSA-N

物化性质

• 沸点：
  297.6±50.0 °C(Predicted)
• 密度：
  0.98±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.91
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl (E)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hept-6-enoate 在 N-乙基吗啉 、 盐酸 、 potassium phosphate 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.83h， 生成
  参考文献：
  名称：

  [EN] REVERSIBLE MACROCYCLIC KINASE INHIBITORS
  [FR] INHIBITEURS DE KINASE RÉVERSIBLES MACROCYCLIQUES

  摘要：

  The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors. Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicament, in particular for the treatment specific kinase mediated disorders, such as cancer.

  公开号：

  WO2023110936A1
• 作为产物：
  描述：

  甲基6-庚炔酸酯 、 频那醇硼烷 在 bis(cyclohexanyl)borane 作用下， 反应 4.0h， 以12%的产率得到methyl (E)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hept-6-enoate
  参考文献：
  名称：

  硼酸酯的乙烯基取代中的立体化学转化，生成碘鎓盐：内部氧基团的参与。

  摘要：

  [反应：参见正文]在BF（3）.OEt（2）的存在下，使用具有酰氧基，烷氧基或甲氧基羰基的烯基硼酸酯与（二乙酰氧基碘）苯反应，以提供具有反转构型的烯基碘鎓四氟硼酸酯： （E）-和（Z）-硼酸酯分别得到（Z）-和（E）-碘鎓盐。通过将醚添加到二氯甲烷溶液中可以逆转这种选择性。立体选择性可以通过相邻氧基的参与来解释。

  DOI：

  10.1021/ol0601850

文献信息

• Nickel-Catalyzed Highly Selective Hydroalkenylation of Alkenyl Boronic Esters to Access Allyl Boron
  作者：Penglin Zhang、Min Zhang、Yuqi Ji、Mimi Xing、Qian Zhao、Chun Zhang

  DOI：10.1021/acs.orglett.0c02923

  日期：2020.11.6

  Allyl boron derivatives are valuable building blocks in the synthesis of natural products and bioactive molecules. Herein, a practical strategy of nickel-catalyzed highly selective hydroalkenylation of alkenyl boronic esters was developed. Under the mild reaction conditions, a variety of allyl boronic esters were accessed with excellent chemo- and regioselectivity. The mechanism of this transformation

  烯丙基硼衍生物是天然产物和生物活性分子合成中的重要组成部分。本文中，开发了镍催化的烯基硼酸酯的高选择性加氢烯基化的实用策略。在温和的反应条件下，可以得到具有优异的化学和区域选择性的各种烯丙基硼酸酯。通过控制实验和动力学研究说明了这种转化的机理。
• Copper-Catalyzed Highly Selective Hydrosilylation of Silyl or Boryl Alkene: A Method for Preparing Chiral Geminated Disilyl and Borylsilyl Reagents
  作者：Min Zhang、Yuqi Ji、Zheng Zhang、Chun Zhang

  DOI：10.1021/acs.orglett.2c00858

  日期：2022.4.15

  The copper-catalyzed highly selective hydrosilylation of silyl or boryl alkene has been developed. This chemistry could afford a practical method for preparing chiral geminated disilyl and borylsilyl reagents, which are useful organosilanes and versatile synthons for organic synthesis. The experimental data suggested that this reaction could be compatible with a variety of functional groups. Furthermore

  已经开发了铜催化的甲硅烷基或硼基烯烃的高选择性氢化硅烷化。这种化学方法可以提供一种实用的方法来制备手性双甲硅烷基和硼基甲硅烷基试剂，它们是有用的有机硅烷和用于有机合成的多功能合成子。实验数据表明该反应可以与多种官能团相容。此外，可以通过这种化学方法制备的偕二金属化合物的实用性已通过进一步的转化得到很好的说明。
• Stereochemical Inversion in the Vinylic Substitution of Boronic Esters To Give Iodonium Salts:  Participation of the Internal Oxy Group
  作者：Morifumi Fujita、Hee Jin Lee、Tadashi Okuyama

  DOI：10.1021/ol0601850

  日期：2006.3.1

  [reaction: see text] Alkenylboronic esters having an acyloxy, alkoxy, or methoxycarbonyl group were employed for the reaction with (diacetoxyiodo)benzene in the presence of BF(3).OEt(2) to provide the alkenyliodonium tetrafluoroborates with inversion of configuration: (E)- and (Z)-boronates give (Z)- and (E)-iodonium salts, respectively. This selectivity can be reversed by the addition of ether to

  [反应：参见正文]在BF（3）.OEt（2）的存在下，使用具有酰氧基，烷氧基或甲氧基羰基的烯基硼酸酯与（二乙酰氧基碘）苯反应，以提供具有反转构型的烯基碘鎓四氟硼酸酯： （E）-和（Z）-硼酸酯分别得到（Z）-和（E）-碘鎓盐。通过将醚添加到二氯甲烷溶液中可以逆转这种选择性。立体选择性可以通过相邻氧基的参与来解释。
• [EN] REVERSIBLE MACROCYCLIC KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE RÉVERSIBLES MACROCYCLIQUES
  申请人：[en]NETHERLANDS TRANSLATIONAL RESEARCH CENTER HOLDING B.V

  公开号：WO2023110936A1

  公开（公告）日：2023-06-22

  The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors. Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicament, in particular for the treatment specific kinase mediated disorders, such as cancer.